PepEvolution
Our Moat

Sourcing Transparency Report

The peptide market is intentionally opaque. Chinese factories supply both FDA-regulated pharmacies and unregulated "research" vendors — often from the same batch. Here's what the supply chain actually looks like.

Research compiled June 2026. Sources linked throughout. Regulatory landscape actively evolving — verify before acting.

The Supply Chain

Tier 1 — API Manufacturers
Chinese API houses · Western pharma CDMOs
Mandybio · WuXi TIDES · GL Biochem · Enogen · Bachem · PolyPeptide
↓
Path A — Pharmaceutical
503A compounding pharmacies (patient Rx)
503B outsourcing facilities (batch Rx)
FDA-regulated · Prescription required · Quality controls
Path B — Research/Gray Market
US/EU importers & white-label repackagers
"Research use only" retail vendors
Unregulated · No prescription · Variable quality
↓
Tier 3 — End Customer
Path A: Patient (via prescription)
Path B: Individual buyer (nominally "researcher")

Key insight: The raw peptide material for both paths often originates from the same upstream Chinese API manufacturers — but diverges sharply in regulatory oversight and quality controls at Tier 2.

503A vs. 503B: What They Mean

503A Compounding Pharmacy503B Outsourcing Facility
RegulatorState pharmacy board + some FDAFDA (cGMP, federally inspected)
ScalePatient-specific, small batchLarge batch, can supply clinics/hospitals
PrescriptionYes, per patientNot required (office stock)
Peptide compoundingMore flexibility if Category 1Essentially none — no peptides on 503B Bulks List
BPC-157 / TB-500 (June 2026)Gray zone — removed from Cat. 2, not yet authorizedEven stricter — not authorized
Semaglutide / TirzepatideProhibited since April/May 2025Permanently excluded (proposed April 2026)

April 2026 milestone: FDA removed ~12 peptides from Category 2 (including BPC-157 and TB-500) after nominators withdrew. This does NOT authorize compounding — they're in a gray zone. The July 23–24, 2026 PCAC meeting is the next key event for FDA review of BPC-157, TB-500, KPV, Semax, Epitalon, and others.

Named Chinese API Manufacturers (Upstream)

Research-grade vendors almost universally source from Chinese API manufacturers but rarely disclose the specific factory. These are the upstream suppliers visible in community research and Janoshik public test metadata:

Hangzhou Mandy Biotechnology (MandyBio)

Most visible
Hangzhou, China

Most frequently named in community research. Appears directly on Janoshik public test submissions. Sells direct-to-consumer internationally. Tracked by Finnrick. Accepts crypto.

GL Biochem (Shanghai) Ltd.

Community-cited quality
Shanghai, China

Founded 1999. 8 global production sites. SPPS at mg-to-kg scale. Most frequently cited in community as a known-quality upstream source — but no confirmed direct supply to any named US vendor has been publicly documented.

Enogen (Hangzhou Enogen Biotech)

FDA Green List
Zhejiang, China

GLP-1 APIs on FDA's Green List (approved for US import). Pharmaceutical-grade — one of the few Chinese manufacturers with FDA approval for specific peptides.

WuXi TIDES (WuXi AppTec)

Pharma-grade only
Changzhou/Taixing, China

Major pharma CDMO. 100,000L+ SPPS capacity (2025). $1.65B TIDES revenue 2025 (+96% YoY). Serves global top-20 pharma companies — NOT research vendors. BIOSECURE Act risk causing some pharma clients to diversify.

Conscientia Industrial

China

Claims in-house SPPS manufacturing for BPC-157. Industrial supply, global shipping.

Xi'an Sonwu Biotech

Xi'an, China

BPC-157 and other peptide APIs. B2B and direct.

Third-Party Testing: Who Verifies What

Janoshik Analytical (Czech Republic)

The community standard
  • • ~60,000 samples/year as of April 2026
  • • HPLC/MS purity, identity, and quantitative testing
  • • Public results: public.janoshik.com
  • • Verify any COA at janoshik.com/verify
  • • Not ISO 17025 accredited (limitation)

Finnrick Analytics (US)

Independent purchase-and-test
  • • Texas-based; buys retail products, tests independently
  • • ~1/3 of products tested fail basic quality checks
  • • Tracks Mandybio, Limitless Life, Loti Labs, and others
  • • Accepts community sample submissions
  • • Site: finnrick.com

Vendors using Janoshik (confirmed COAs with verification links)

Panda PeptidesDurham PeptidesPrime PeptidesChameleon PeptidesEternal Peptides

Red flags in any COA

  • • No named third-party lab
  • • COAs shared across multiple vendors (sign of same batch, possibly fabricated)
  • • No batch/lot number matching your vial
  • • Summary numbers only — no full HPLC chromatograms
  • • "Available on request" with no public database

Most Transparent Research Vendors (COA Quality)

#1
Protide Health
Public COA archive; batch-specific HPLC + LC-MS; endotoxin testing
#2
Pure Health Peptides
Dual-publication (vendor + Ethos Analytics); lot-specific public library
#3
Loti Labs
Public COA pages per product; Finnrick-verified; USA-based testing
#4
AminoVault
Dual ISO/IEC 17025-accredited third-party testing
#5
Prime Peptides
Janoshik with verifiable public keys on all products

Rankings based on community consensus as of June 2026. Not an endorsement — verify independently.

Pharma-Grade API Manufacturers (Top Tier)

These CDMOs supply branded drug makers — not research vendors, not compounding pharmacies. They represent the gold standard with GMP certification and FDA/EMA regulatory filings.

Bachem Holding AG
Switzerland

50+ years; ~two-thirds of all approved peptide APIs globally; CHF 695M revenue (2025); explicitly non-China supply chain. Supplies Ozempic/Wegovy upstream.

PolyPeptide Group
Switzerland

Founded 1952 (oldest peptide CDMO); 6 GMP sites (EU/US/India); 1,000+ peptides in GMP quality; serves 250+ pharma/biotech clients.

AmbioPharm
North Augusta, SC (US)

US-headquartered; FDA-inspected; $121.9M expansion targeting 2027 commercial scale. "China +1" alternative for pharma.

Sinopep-Allsino
Hangzhou + Lianyungang, China

FDA-inspected (4 successful inspections); 20–30 metric tons peptide/year; 500 kg/year semaglutide and tirzepatide capacity.

Critical distinction: Bachem explicitly highlights a non-China supply chain as a selling point for pharma clients. Bachem and PolyPeptide do NOT supply research vendors or US compounding pharmacies — they serve finished-drug manufacturers exclusively.

Notable Enforcement Actions & Incidents

Amino Asylum — Federal Raid & Guilty Plea

FDA warehouse raid ~June 18, 2025 (Memphis, TN). Founders Matthew Kawa & Jennifer Stechkober pleaded guilty Dec 10, 2025 to selling products containing testosterone labeled as SARMs and selling unapproved drugs. Site permanently offline.

Peptide Sciences — Voluntary Shutdown

Voluntary shutdown March 6, 2026. ~$7.4M/month estimated sales. Posted 3-sentence notice and went dark. Attributed to regulatory pressure and product quality concerns.

Swiss Chems — FDA Warning Letter

FDA Warning Letter Dec 10, 2024 for selling semaglutide and retatrutide as unapproved drugs. "Research use only" defense explicitly rejected. Site remains operational.

Aequita Pharmacy — Washington DOH Raid

Washington State DOH raided Aequita in 2025 for violations including imported low-cost peptide powders and contamination risks. Partner Mochi Health paused the relationship.

GenoGenix — FDA Warning + Production Ceased

FDA warning letter Dec 2025. 3 patient ER visits. Major recall July 2025. Production ceased.

Primary Sources

Educational only — not medical advice. Information compiled from public sources. Consult a licensed healthcare provider before using any compound.